Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma

Dendritic cell (DC)-based immunotherapy has been applied to glioblastoma (GBM); however, biomarkers informing response remain poorly understood. We conducted a phase I/IIa clinical trial investigating tumor-fused DC (TFDC) immunotherapy following temozolomide-based chemoradiotherapy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Takei, Jun, Kamata, Yuko, Tanaka, Toshihide, Fukasawa, Nei, Gomisawa, Kazutaka, Satake, Mari, Mori, Ryosuke, Yamamoto, Yohei, Suzuki, Tomoya, Oda, Ayaka, Murahashi, Mutsunori, Fukuda, Takahiro, Shimoda, Masayuki, Murayama, Yuichi, Akasaki, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491709/
https://www.ncbi.nlm.nih.gov/pubmed/37382632
http://dx.doi.org/10.1007/s00262-023-03482-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491709/
https://www.ncbi.nlm.nih.gov/pubmed/37382632
http://dx.doi.org/10.1007/s00262-023-03482-8

Ejemplares similares